The study identified several potential adverse effects of TYK2 inhibitors, including headache, upper respiratory tract infection, nausea, diarrheal, increased circulating levels of creatinine and liver enzymes, and risk of certain malignant neoplasms, such prostate and breast cancer. The gene discussed is TYK2; the disease is Recurrent upper respiratory tract infections.